Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitorChengying Xie, Liguang Lou|Cancer Science|2018Cited by 368
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonistChengying Xie, Liguang Lou|Journal of Cellular and Molecular Medicine|2018Cited by 59
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemiaYujun Chen, Chengying Xie|Acta Pharmacologica Sinica|2025Cited by 5